Did you buy SLNO common stock between March 26, 2025, and November 4, 2025? Affected Soleno Therapeutics, Inc. Investor Summary RADNOR, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO) on behalf of those who purchased or acquired Soleno common stock between March 26, 2025, and ...

New York, New York--(Newsfile Corp. - March 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Plug Power Inc. (NASDAQ: PLUG) between January 17, 2025 and November 13, 2025, inclusive (the "Class Period"), of the important April 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased Plug Power securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Viewpoint - Micron reported strong quarterly earnings of $12.2 per share, significantly exceeding the Zacks Consensus Estimate of $8.8 per share, and showing a substantial increase from $1.56 per share a year ago, indicating robust performance in the semiconductor industry [1] Financial Performance - The company achieved revenues of $23.86 billion for the quarter ended February 2026, surpassing the Zacks Consensus Estimate by 21.67%, and showing a remarkable increase from $8.05 billion year-over-year [2] - Over the last four quarters, Micron has consistently exceeded consensus EPS estimates, indicating a strong operational performance [2] Stock Performance - Micron shares have increased approximately 61.8% since the beginning of the year, contrasting with a 1.9% decline in the S&P 500, showcasing the stock's strong market performance [3] Future Outlook - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $11.04 for the coming quarter and $36.18 for the current fiscal year [7] - The Zacks Rank for Micron is currently 1 (Strong Buy), suggesting that the stock is expected to outperform the market in the near future based on favorable estimate revisions [6] Industry Context - The Computer - Integrated Systems industry, to which Micron belongs, is currently ranked in the top 10% of over 250 Zacks industries, indicating a favorable environment for the company's performance [8]

Core Insights - Five Below (FIVE) reported quarterly earnings of $4.31 per share, exceeding the Zacks Consensus Estimate of $3.99 per share, and showing an increase from $3.48 per share a year ago, resulting in an earnings surprise of +8.02% [1] - The company achieved revenues of $1.73 billion for the quarter ended January 2026, surpassing the Zacks Consensus Estimate by 1.14%, and up from $1.39 billion year-over-year [2] - Five Below has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The sustainability of Five Below's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is $0.89 on revenues of $1.1 billion, and for the current fiscal year, it is $6.94 on revenues of $5.18 billion [7] Industry Context - The Retail - Miscellaneous industry, to which Five Below belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges in overall industry performance [8] - Empirical research suggests a strong correlation between near-term stock movements and earnings estimate revisions, which can impact Five Below's stock performance [5]

Core Insights - Alvotech reported total revenues of $593 million for FY 2025, reflecting a 21% year-on-year increase [3] - The company has launched three newly approved biosimilars and has a pipeline of 30 biosimilars in development [5][6] - Alvotech anticipates total revenues of $650-700 million for 2026, with adjusted EBITDA expected to rise to $180-220 million [11] Financial Performance - Total revenues for Q4 2025 were $173 million, a 13% increase year-on-year [7] - Adjusted EBITDA for FY 2025 was $137 million, up 27% year-on-year, with a gross margin of 61% [7] - The cash balance as of December 31, 2025, was $172 million [7] Product Development and Approvals - Alvotech has five approved biosimilars on the market, including products referencing Humira®, Stelara®, and Simponi® [18] - Recent approvals include AVT05 as a biosimilar to Simponi® and AVT03 as a biosimilar to Prolia® and Xgeva® in the EEA [7] - The company expects to receive U.S. approval for four Biologics License Applications by late 2026 [12] Strategic Initiatives - Alvotech raised nearly $300 million from capital markets to support its development programs and manufacturing platform [6] - The company has expanded its global reach through new commercial partnerships and acquisitions, including the R&D organization of Xbrane in Sweden [6][7] - Leadership changes include the appointment of Lisa Graver as Chief Executive Officer and other key management roles [10] Market Outlook - Management reaffirms its outlook for 2026, focusing on cash flow and margin expansion [11] - The anticipated revenue range for 2026 reflects continued double-digit sales growth [11] - The company is addressing regulatory observations from the FDA inspection of its Reykjavik manufacturing facility and plans to resubmit applications in Q2 2026 [9]

Core Viewpoint - Acceleware Ltd. is planning a restructuring of its outstanding debt owed to 10% unsecured convertible debenture holders, amounting to up to $2,400,000, which includes total principal and accrued unpaid interest [1]. Details of Debenture Restructuring - The company offers existing debenture holders the option to convert their outstanding amounts into units consisting of one common share and one warrant, with the warrant allowing the purchase of a common share at $0.20 for 24 months [2]. - If the common shares trade at or above $0.30 for 30 consecutive trading days, Acceleware may accelerate the expiry of the warrants [3]. Replacement Debentures - Replacement debentures will have a maturity of four years and a conversion price of $0.15, with each convertible into units comprising one common share and half a warrant [4]. Expected Completion - The company anticipates completing the debenture restructuring around March 24, 2026, with further details to be provided in a subsequent release [5]. Conditions for Completion - Completion is subject to regulatory approvals, debenture holder elections, and finalization of agreements, with no assurance that the restructuring will occur as described [6]. Insider Participation - Certain insiders are expected to participate in the restructuring, classifying it as a related party transaction, and the company will rely on exemptions from formal valuation and minority approval requirements [7]. Company Overview - Acceleware specializes in advanced electromagnetic heating technology, providing proprietary RF power-to-heat solutions aimed at increasing production and reducing energy consumption in industrial heating [8]. - The company is involved in multiple projects across sectors, including mining and amine regeneration, and is publicly listed on the TSX Venture Exchange under the symbol "AXE" [9].

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a securities fraud lawsuit, with a lead plaintiff deadline set for April 7, 2026, for investors who purchased securities during the specified class period from October 10, 2023, to December 26, 2025 [1]. Group 1: Lawsuit Details - The lawsuit alleges that during the class period, Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - The lawsuit asserts that when the true details became public, investors suffered damages due to the misleading statements made by the defendants [5]. Group 2: Class Action Participation - Investors who purchased Inovio securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A class has not yet been certified, meaning investors are not represented by counsel unless they retain one, and participation as a lead plaintiff is not necessary for potential recovery [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Boston Scientific Corporation common stock between July 23, 2025, and February 3, 2026, of the May 4, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Boston Scientific common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that Boston Scientific made misleading statements about its U.S. Electrophysiology segment, leading to a net income miss and disappointing guidance for the first half of fiscal 2026 [5]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Trip.com Group Limited securities between April 30, 2024, and January 13, 2026, about the May 11, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Trip.com securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that defendants made false or misleading statements regarding Trip.com's regulatory risks and business operations, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - The Camping World Holdings, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and inadequate disclosures regarding its financial health and inventory management practices [1][3]. Company Allegations - The lawsuit alleges that Camping World overstated its inventory management capabilities and retail demand, which led to a need for corrective inventory management that negatively impacted gross profit and margins [3]. - Specific allegations include that Camping World failed to disclose its inadequate systems for ensuring accurate financial disclosures and guidance regarding its balance sheet and operational expenses [3]. Financial Performance - In the third quarter of 2025, Camping World reported new vehicle revenue of $766.8 million, a decrease of $58.1 million or 7.0%, with the average selling price of new vehicles sold decreasing by 8.6% [4]. - The gross margin for new vehicles was reported at 12.7%, down 81 basis points, primarily due to the decrease in average selling price [4]. - Following the release of these results, Camping World shares fell nearly 25% [4]. - In the fourth quarter of 2025, the company announced strict inventory management objectives and paused its quarterly cash dividend, which led to a further decline in share price of more than 16% [5]. Legal Process - Investors who purchased Camping World securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [6]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [7][8].